Evidence map›Paper›PMID 38787065›Full record

ArticleToxins2024

High-Performance Liquid Chromatography-Fluorescence Detection Method for Ochratoxin A Quantification in Small Mice Sample Volumes: Versatile Application across Diverse Matrices Relevant for Neurodegeneration Research.

Elba Beraza, Maria Serrano-Civantos, Maria Izco, Lydia Alvarez-Erviti, Elena Gonzalez-Peñas, Ariane Vettorazzi

Abstract read
In one paragraph

Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elba BerazaMITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.
Maria Serrano-CivantosMITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.
Maria IzcoLaboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Piqueras 98, 26006 Logroño, Spain.ORCID 0000-0003-4807-6779
Lydia Alvarez-ErvitiLaboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Piqueras 98, 26006 Logroño, Spain.ORCID 0000-0002-1238-9442
Elena Gonzalez-PeñasMITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-1413-0829
Ariane VettorazziMITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-9182-8417

Funding

Government of Navarra (Project-43, 2019 modality A) and the and European Regional Develop-ment Fund (ERDF under Operational Program for Navarra, 2014-2020 (Project-43, 2019 modality A)
6 · The paper itself

Abstract

Ochratoxin A (OTA) is a mycotoxin commonly found in various food products, which poses potential health risks to humans and animals. Recently, more attention has been directed towards its potential neurodegenerative effects. However, there are currently no fully validated HPLC analytical methods established for its quantification in mice, the primary animal model in this field, that include pivotal tissues in this area of research, such as the intestine and brain. To address this gap, we developed and validated a highly sensitive, rapid, and simple method using HPLC-FLD for OTA determination in mice tissues (kidney, liver, brain, and intestine) as well as plasma samples. The method was rigorously validated for selectivity, linearity, accuracy, precision, recovery, dilution integrity, carry-over effect, stability, and robustness, meeting the validation criteria outlined by FDA and EMA guidelines. Furthermore, the described method enables the quantification of OTA in each individual sample using minimal tissue mass while maintaining excellent recovery values. The applicability of the method was demonstrated in a repeated low-dose OTA study in Balb/c mice, which, together with the inclusion of relevant and less common tissues in the validation process, underscore its suitability for neurodegeneration-related research.

Indexed as

Mice, Inbred BALB COchratoxinsAnimalsChromatography, High Pressure LiquidFemaleKidneyMaleMiceNeurodegenerative DiseasesReproducibility of ResultsSpectrometry, FluorescenceTissue Distributionochratoxin AOchratoxinsbrainHPLC-FLDmouseochratoxin Aplasmatissues

Identifiers

PMID38787065
PMCPMC11125890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.